Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-25-000764
Filing Date
2025-08-13
Accepted
2025-08-13 19:43:50
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 24554
2 JOINT FILING AGREEMENT ss5208859_ex9901.htm EX-99.1 7393
  Complete submission text file 0000947871-25-000764.txt   33755
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SCHEDULE 13D/A

Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent BioPharma, Inc. (Subject) CIK: 0001868279 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-94331 | Film No.: 251213647
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)